Business Description
CervoMed Inc
NAICS : 325414
SIC : 2834
ISIN : US15713L1098
Total Employee Number:
15Description
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.7 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 34.6 | |||||
3-Year EPS without NRI Growth Rate | 35.7 | |||||
3-Year FCF Growth Rate | 19.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.01 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.63 | |||||
9-Day RSI | 41.42 | |||||
14-Day RSI | 44.96 | |||||
3-1 Month Momentum % | -39.36 | |||||
6-1 Month Momentum % | -64.95 | |||||
12-1 Month Momentum % | -65.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.36 | |||||
Quick Ratio | 3.36 | |||||
Cash Ratio | 2.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -89.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -122.17 | |||||
ROA % | -103.39 | |||||
ROIC % | -3333.65 | |||||
3-Year ROIIC % | 213.33 | |||||
ROCE % | -126.51 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.68 | |||||
Price-to-Tangible-Book | 2.68 | |||||
EV-to-EBIT | -0.5 | |||||
EV-to-Forward-EBIT | -0.42 | |||||
EV-to-EBITDA | -0.5 | |||||
EV-to-Forward-EBITDA | -0.45 | |||||
EV-to-Forward-Revenue | 61.31 | |||||
EV-to-FCF | -0.57 | |||||
| Price-to-Net-Current-Asset-Value | 2.68 | |||||
| Price-to-Net-Cash | 3.38 | |||||
Earnings Yield (Greenblatt) % | -200 | |||||
FCF Yield % | -96.7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRVO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CervoMed Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.28 | ||
| Beta | -4.8987 | ||
| 3-Year Sharpe Ratio | 0.48 | ||
| 3-Year Sortino Ratio | 1.52 | ||
| Volatility % | 78.37 | ||
| 14-Day RSI | 44.96 | ||
| 14-Day ATR ($) | 0.512624 | ||
| 20-Day SMA ($) | 3.5295 | ||
| 12-1 Month Momentum % | -65.54 | ||
| 52-Week Range ($) | 2.13 - 13.13 | ||
| Shares Outstanding (Mil) | 9.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CervoMed Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CervoMed Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 118 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 27 days | ||
| H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | 2026-06-15 07:00 | 2.45 (-1.61%) | ||
| General meeting for 2026 | 2026-06-08 09:00 | 2.94 (-5.77%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 3.76 (+1.08%) | ||
| 8(th) Annual ROTH Conference | 2026-03-23 12:00 | 4.02 (-4.96%) | ||
| Annual report for 2025 | 2026-03-13 | 4.33 (-2.70%) | ||
| Third quarter earnings results for 2025 | 2025-11-10 | 6.92 (-2.67%) | ||
| Emerging Growth Conference | 2025-10-22 11:25 | 7.22 (-3.09%) | ||
| H.C. Wainwright 27(th) Annual Global Investment Conference | 2025-09-08 14:00 | 10.51 (+2.44%) |
Show
Entries
CervoMed Inc Frequently Asked Questions
What is CervoMed Inc(CRVO)'s stock price today?
The current price of CRVO is $3.08. The 52 week high of CRVO is $13.13 and 52 week low is $2.13.
When is next earnings date of CervoMed Inc(CRVO)?
The next earnings date of CervoMed Inc(CRVO) is 2026-08-11 Est..
Does CervoMed Inc(CRVO) pay dividends? If so, how much?
CervoMed Inc(CRVO) does not pay dividend.
Guru Commentaries on NAS:CRVO
No articles.
Press Release
Articles on CervoMed Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers